Detection of anti-Trypanosoma cruzi antibodies by chimeric antigens in chronic Chagas disease-individuals from endemic South American countries.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
01
2019
accepted:
04
04
2019
entrez:
19
4
2019
pubmed:
19
4
2019
medline:
8
1
2020
Statut:
epublish
Résumé
Laboratory diagnosis of chronic Chagas disease is a troubling factor due to lack of reference tests. The WHO suggests the use of two distinct commercial serological tests in parallel. The performance of commercial immunoassays might fluctuate depending on the antigenic matrices and the local strains of T. cruzi in different geographical settings. The use of antigenic matrices based on chimeric proteins can solve these limitations. Here, we evaluated the diagnostic performance of two chimeric T. cruzi antigens (IBMP-8.1 and -8.4) to diagnose chronic Chagas disease in individuals from endemic South American countries. IBMP-8.1 and IBMP-8.4 chimeric antigens were expressed as soluble proteins in E. coli and purified using chromatography methods. Reactivity of IBMP-8.1 and IBMP-8.4 was assessed using an in-house ELISA with sera from 122 non-infected and 215 T. cruzi-infected individuals from Argentina, Bolivia, and Paraguay. Cut-off values were based on ROC curves and performance parameters were determined using a dichotomous approach. Area under the curve values were > 99.7% for both IBMP-8.1 and IBMP-8.4 antigens. IgG levels in T. cruzi-positive and negative samples were higher for IBMP-8.4 than IBMP-8.1. Both IBMP-8.1 and -8.4 were 100% specific, while IBMP-8.4 were 100% sensitive compared to IBMP-8.1 (95.3%). Admitting RI values of 1.0 ± 0.10 as the inconclusive interval, 6.2% of the samples tested using IBMP-8.1 and 2.1% using IBMP-8.4 fell inside the grey zone. Based on accuracy and diagnostic odds ratio values, IBMP-8.4 presented the best performance. Differences in sensitivity and IgG levels among the samples from Argentina, Bolivia, and Paraguay were not significant. Our findings showed a notable performance of IBMP-8.1 and -8.4 chimeric antigens in diagnosing chronic Chagas disease in individuals from endemic South American countries, confirming our hypothesis that these antigens could be used in geographical areas where distinct T. cruzi DTUs occur.
Sections du résumé
BACKGROUND
Laboratory diagnosis of chronic Chagas disease is a troubling factor due to lack of reference tests. The WHO suggests the use of two distinct commercial serological tests in parallel. The performance of commercial immunoassays might fluctuate depending on the antigenic matrices and the local strains of T. cruzi in different geographical settings. The use of antigenic matrices based on chimeric proteins can solve these limitations. Here, we evaluated the diagnostic performance of two chimeric T. cruzi antigens (IBMP-8.1 and -8.4) to diagnose chronic Chagas disease in individuals from endemic South American countries.
METHODOLOGY/PRINCIPAL FINDINGS
IBMP-8.1 and IBMP-8.4 chimeric antigens were expressed as soluble proteins in E. coli and purified using chromatography methods. Reactivity of IBMP-8.1 and IBMP-8.4 was assessed using an in-house ELISA with sera from 122 non-infected and 215 T. cruzi-infected individuals from Argentina, Bolivia, and Paraguay. Cut-off values were based on ROC curves and performance parameters were determined using a dichotomous approach. Area under the curve values were > 99.7% for both IBMP-8.1 and IBMP-8.4 antigens. IgG levels in T. cruzi-positive and negative samples were higher for IBMP-8.4 than IBMP-8.1. Both IBMP-8.1 and -8.4 were 100% specific, while IBMP-8.4 were 100% sensitive compared to IBMP-8.1 (95.3%). Admitting RI values of 1.0 ± 0.10 as the inconclusive interval, 6.2% of the samples tested using IBMP-8.1 and 2.1% using IBMP-8.4 fell inside the grey zone. Based on accuracy and diagnostic odds ratio values, IBMP-8.4 presented the best performance. Differences in sensitivity and IgG levels among the samples from Argentina, Bolivia, and Paraguay were not significant.
CONCLUSIONS/SIGNIFICANCE
Our findings showed a notable performance of IBMP-8.1 and -8.4 chimeric antigens in diagnosing chronic Chagas disease in individuals from endemic South American countries, confirming our hypothesis that these antigens could be used in geographical areas where distinct T. cruzi DTUs occur.
Identifiants
pubmed: 30998741
doi: 10.1371/journal.pone.0215623
pii: PONE-D-19-09603
pmc: PMC6472793
doi:
Substances chimiques
Antibodies, Protozoan
0
Antigens, Protozoan
0
Immunoglobulin G
0
Recombinant Fusion Proteins
0
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0215623Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Trop Med Hyg. 2015 Jul;93(1):108-13
pubmed: 25986581
Acta Trop. 2018 Aug;184:38-52
pubmed: 28941731
Acta Trop. 2016 Apr;156:68-78
pubmed: 26777312
J Protozool. 1982 Aug;29(3):430-7
pubmed: 6182288
Int J Parasitol. 2009 Oct;39(12):1305-17
pubmed: 19393242
PLoS Negl Trop Dis. 2017 Mar 8;11(3):e0005433
pubmed: 28273127
BMC Infect Dis. 2019 Mar 12;19(1):251
pubmed: 30871504
Expert Rev Anti Infect Ther. 2015 Aug;13(8):995-1029
pubmed: 26162928
PLoS Negl Trop Dis. 2012;6(5):e1498
pubmed: 22666504
PLoS One. 2016 Aug 12;11(8):e0161100
pubmed: 27517281
Mol Biochem Parasitol. 2004 Nov;138(1):131-41
pubmed: 15500924
Am J Trop Med Hyg. 2014 Jun;90(6):1074-81
pubmed: 24710614
Acta Paediatr. 2007 Apr;96(4):487-91
pubmed: 17306009
Parasitol Int. 2017 Apr;66(2):83-88
pubmed: 27940065
PLoS Negl Trop Dis. 2016 Aug 29;10(8):e0004792
pubmed: 27571035
Lancet Infect Dis. 2001 Sep;1(2):92-100
pubmed: 11871482
Cad Saude Publica. 2007 Oct;23(10):2263-74
pubmed: 17891288
J Clin Microbiol. 2017 Oct;55(10):2934-2945
pubmed: 28724556
Acta Trop. 2010 Jul-Aug;115(1-2):14-21
pubmed: 19932071
Rev Soc Bras Med Trop. 2016 Dec;49Suppl 1(Suppl 1):3-60
pubmed: 27982292
Rev Soc Bras Med Trop. 2008 May-Jun;41(3):315-9
pubmed: 18719818
J Clin Epidemiol. 2003 Nov;56(11):1129-35
pubmed: 14615004
Mem Inst Oswaldo Cruz. 2014 Sep;109(6):828-33
pubmed: 25317712
BMJ Open. 2016 Nov 14;6(11):e012799
pubmed: 28137831
Am J Trop Med Hyg. 2009 Mar;80(3):410-5
pubmed: 19270291
Parasitol Today. 1991 Sep;7(9):228-32
pubmed: 15463504
Infect Genet Evol. 2012 Mar;12(2):240-53
pubmed: 22226704
Acta Trop. 2010 Jul-Aug;115(1-2):55-68
pubmed: 19900395